AI meets Rx-Study 24/25

Highlights of the AI meets Rx Study 24/25

Exclusive Rx manufacturer survey: Results of the Rx manufacturer survey on the topic of AI in the Rx business
Unique opportunities with AI: Smarter use of AI in content management, pharmacovigilance and field sales
Market insights & forecast: Forecasts of potential €12 billion Rx sales by 2030
Online pharmacy focus: Eight top opportunities for Rx pharmaceutical manufacturers to work with online pharmacies
Insights into physician behaviour: How doctors prefer to inform themselves about professional topics

The introduction of e-prescriptions in Germany and ongoing digitalisation are opening up new and promising opportunities for the Rx market and the digital pharmacy industry – but they also present challenges. With a projected market volume of €12 billion by 2030, the eRx market is on a growth trajectory. The implementation of the CardLink procedure and the option of digitally dispensing e-prescriptions make this area particularly attractive for pharmaceutical manufacturers. Partnerships with e-pharmacies open up new avenues for personalised patient engagement and innovative marketing campaigns. There are many good reasons for Rx manufacturers to take a closer look at the German digital pharmaceutical market and discover the potential that awaits them.

The study ‘AI meets Rx’ shows the added value that AI-based tools can offer for research, marketing and field service and how the new digital focus supports collaboration between pharmaceutical companies and e-pharmacies. The results of the study's Rx manufacturer survey underscore the fact that the Rx industry is increasingly recognising AI solutions as an important support. The analysis also addresses specific recommendations for action and tools that are ideal for use in day-to-day Rx business. The study is rounded off by insights into current market insights and findings on physicians' information behaviour.